{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:25:15Z","timestamp":1792488315812,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Glucocorticoids (GC) are the standard of care for the induction and maintenance of remission in immunoglobulin G4 (IgG4)-related diseases. However, IgG4-related diseases often relapse with GC dose reduction, not only making GC dose reduction difficult but also necessitating GC dose escalation in many cases. Therefore, other immunosuppressive drugs are required to maintain remission. Here, we report a 39-year-old man with ulcerative colitis and IgG4-related disease who experienced a relapse of both diseases despite treatment with tacrolimus and 6-mercaptopurine. Following the initiation of tofacitinib, a Janus-associated kinase inhibitor, it was possible to reduce the GC dose while maintaining remission of both diseases. This case highlights the potential utility of Janus-associated kinase inhibitors in managing complex cases of IgG4-related disease, especially those with concurrent conditions such as ulcerative colitis.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae025","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T09:25:29Z","timestamp":1715765129000},"page":"339-343","source":"Crossref","is-referenced-by-count":6,"title":["A case of IgG4-related disease associated with ulcerative colitis that was successfully treated with a JAK inhibitor"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3747-7200","authenticated-orcid":false,"given":"Tomonao","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Aochi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-2484","authenticated-orcid":false,"given":"Motohisa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024083002030012000_R1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/14397595.2014.950036","article-title":"Everyday clinical practice in IgG4-related dacryoadenitis and\/or sialadenitis: results from the SMART database","volume":"25","author":"Yamamoto","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2024083002030012000_R2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024083002030012000_R3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/annrheumdis-2016-209368","article-title":"Efficacy of abatacept for IgG4-related disease over 8 months","volume":"75","author":"Yamamoto","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024083002030012000_R4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2019-216368","article-title":"Dupilumab as a novel steroid-sparing treatment for IgG4-related disease","volume":"79","author":"Simpson","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024083002030012000_R5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"2024083002030012000_R6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.18176\/jiaci.0654","article-title":"JAK inhibition as a therapeutic strategy for IgG4-RD","volume":"31","author":"Khan","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2024083002030012000_R7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2024083002030012000_R8","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut"},{"key":"2024083002030012000_R9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn\u2019s disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2024083002030012000_R10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/jgh.15894","article-title":"Prevalence and clinical features of patients with autoimmune pancreatitis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"37","author":"Fukuda","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2024083002030012000_R11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2024083002030012000_R12","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"2024083002030012000_R13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/intimm\/dxz073","article-title":"Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease","volume":"32","author":"Sasaki","year":"2020","journal-title":"Int Immunol"},{"key":"2024083002030012000_R14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.922307","article-title":"IL-7 promotes the expansion of circulating CD28- cytotoxic T Lymphocytes in patients with IgG4-related disease via the JAK signaling","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"key":"2024083002030012000_R15","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1172\/JCI121668","article-title":"IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease","volume":"129","author":"Belarif","year":"2019","journal-title":"J Clin Invest"},{"key":"2024083002030012000_R16","article-title":"Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae025\/57701437\/rxae025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/2\/339\/58965649\/rxae025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/8\/2\/339\/58965649\/rxae025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T22:03:18Z","timestamp":1724968998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/8\/2\/339\/7674127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae025","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,15]]}}}